The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
The FDA wants to pull its approval of a drug. It’s not so easy.
In short
The Food and Drug Administration is currently working to withdraw its formal authorization for Tavneos. Regulators determined that the therapy originally gained market entry relying on manipulated scientific trial data. Overturning an existing clearance presents substantial administrative obstacles for the agency. Consequently, the lengthy proceedings have sparked significant debate over patient access while the review continues.
Key points
- Regulatory findings of manipulated trial data have jeopardized the market status of Tavne…: Regulatory findings of manipulated trial data have jeopardized the market status of Tavneos.
- Navigating the withdrawal of an approved pharmaceutical involves substantial procedural h…: Navigating the withdrawal of an approved pharmaceutical involves substantial procedural hurdles for regulators.
- Uncertainty persists regarding whether patients will maintain access to Tavneos as procee…: Uncertainty persists regarding whether patients will maintain access to Tavneos as proceedings unfold.